Markets
Hims oral semaglutide
A screenshot from forhers.com showing oral semaglutide (Sherwood News)

Hims reports Q4 earnings beat, revenue miss

The report comes as the company has faced mounting legal troubles related to its short-lived Wegovy pill copy.

Hims & Hers reported mixed financial results and gave lukewarm full-year guidance, moves that come after a tumultuous stretch for the telehealth company. 

For the last three months of 2025, Hims & Hers reported:

  • Earnings per share of $0.08, compared to the $0.04 analysts polled by FactSet were expecting.

  • Revenue of $617.8 million, compared to the $619 million analysts were penciling in.

For the full year in 2026, the company expects:

  • Revenue to hit between $2.7 billion and $2.9 billion, compared to the $2.74 billion analysts are currently expecting.

  • Adjusted EBITDA between $300 million and $375 million, compared to the $369 million Wall Street is expecting. The company said it intends to accept smaller margins in its international business in the short term as it gains market share.

The earnings report comes as the company has faced massive blowback from regulators after it rolled out a copy of Novo Nordisk’s Wegovy pill early this month. Hims is now facing a patent infringement lawsuit from Novo as well as potential charges by the Department of Justice. 

CEO Andrew Dudum declined to comment on ongoing talks with the Food and Drug Administration and the DOJ.

We pulled back to prioritize, honestly, just the engagement and the relationships with the ecosystem of stakeholders, Dudum said. We talked to quite a few of them on launch and understood their dynamics and chose to prioritize them in those conversations, so we decided to pull it.

The stock has also taken a hit: it is down more than 50% since the start of the year, with more than 30% of that drawdown coming after Hims announced the Wegovy pill copies. The stock fell about 4% in after-hours trading following the report.

The company said its outlook assumes that it will continue to be able to sell copycat versions of Novo’s drugs. Throughout the report and call, company executives played down the impact of GLP-1s for its growth prospects.

Today, some may think of us as a GLP-1 company, Dudum said in an X post. The reality is that only a small minority of our subscribers are using a compounded GLP-1 treatment.

As its weight-loss segment sits in a precarious place, the company has focused on expanding into new treatments and geographies.

While Hims does not break out revenue by treatment segment, it did say that more than half of its revenue in 2025 came from “non-GLP-1 offerings” and described compounded GLP-1s as an “incremental growth vector.” Dudum told analysts he expects to add performance, recovery, and sleep in the future. He also said the company is looking into peptide therapies right now.

In the final quarter of 2025, Hims added hormone treatments and labs, including a cancer detection test from Grail. Hims announced last week that it would acquire Eucalyptus, an Australian digital health company, in a deal valued up to $1.15 billion.

Last year, Hims bought Zava, a UK-based peer with a presence in France, Ireland, and Germany, for $265.7 million. It also announced that it would launch in Canada this year offering generic Wegovy. The Eucalyptus acquisition puts Hims in new markets — like Australia and Japan — and gives it a wider presence in other international markets like the United Kingdom, Germany, and Australia. 

The company also broke out its international revenue for the first time: in 2025 if it brought in $133.9 million from outside the US, compared to $26.8 million in 2024.

More Markets

See all Markets
markets

Oklo rises after saying it’s in advanced negotiations on US plutonium recycling

Oklo shares jumped following the announcement that the company has been selected by the US Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program. Under this federal program, Oklo will help to turn excess legacy Cold War nuclear material into commercial fuel for its advanced power plants.

Read more: Inside Oklo’s audacious plan to turn leftover weapons-grade plutonium into a nuclear bridge fuel

Oklo will partner with European nuclear developer Newcleo, validating their October 2025 partnership including a Newcleo-affiliated investment of up to $2 billion, to convert material that already exists into fuel for advanced reactors, using it to generate electricity and consume it through fission.

“Fuel supply constraints are a key throttle to advanced reactor development,” said cofounder and CEO Jacob DeWitte. “This program creates a pathway to use existing surplus material as bridge fuel for advanced reactors to bring more reactors online sooner.”

Advanced nuclear companies are facing roadblocks trying to find fuel. This deal gives Oklo a chance to reduce its dependence on foreign supply chains. Wall Street is closely watching what this means for Oklo’s business model. Wedbush maintained its “outperform” rating and a $110 price target on the stock, emphasizing that this is a helpful “addition” to Oklo’s multipronged fuel strategy, rather than a stand-alone fix.

Just last month, Oklo announced a collaboration with Los Alamos National Laboratory and Nvidia “to support critical infrastructure development and accelerate the deployment of nuclear energy.”

markets

Qualcomm spikes after report that it’s selling “millions” of AI chips to TikTok owner ByteDance

Qualcomm is spiking after a Bloomberg report that the chip company is poised to sell “millions” of AI chips to TikTok owner ByteDance.

The report, citing people familiar with the matter, said these custom processors would be used to “support the social media company’s AI agent software.”

Qualcomm had come under pressure earlier this year because of softness in its China handset business in light of difficulty accessing memory chips, which are in a severe supply crunch. At one time, the company had seemingly been counting on supporting AI-enabled devices to earn its role in the boom — and still might be doing that, with analysts speculating over a potential partnership with OpenAI for an AI smartphone chip.

But it’s also been telegraphing a shift toward playing a bigger role upstream in providing hardware for data centers.

In the press release that accompanied Qualcomm’s recent earnings report, President and CEO Cristiano Amon touted the company’s entry into the data center business, with initial shipments to a “leading hyperscaler” on track for later this year, and said that investors could expect to hear more on Qualcomm’s growth plans in data center and physical AI at its Investor Day on June 24.

Seems like they’re on track.

markets

Peace is great; memory chip stocks are even better

Traders are happy about potential peace. But they’re even more happy that Micron exists.

That’s the best way to describe the price action on Tuesday.

President Donald Trump’s comments this weekend that a deal with Iran has been “largely negotiated,” along with reports that the US Navy has restarted shepherding vessels through the Strait of Hormuz, have contributed to a worldwide rally in stocks and sell-off in crude oil.

Some normal things you’d expect to see are happening:

But... there’s also some weird stuff beneath the hood.

When global stocks outperform the US by a ton, it’s generally because tech is out of favor. After all, the US market is heavily weighted toward megacap tech giants. However, a big reason why ACWX is trouncing the US is because of how insanely well the iShares MSCI South Korea ETF and iShares MSCI Taiwan ETF are doing! Those countries, of course, are even more heavily levered to AI hardware than the US market. The new Street-high view on Micron in particular is fueling gains for Korean stocks, where fellow memory chip giants SK Hynix and Samsung are the biggest components.

The tech-heavy Invesco QQQ Trust is putting in a bigger gain than European stocks, as of 11 a.m. ET.

It’s extremely rare for Europe, a major portion of global equities, to be lagging US tech when ACWX is leaving SPY in the dust.

The combination of global equities outperforming by at least 1% while the Nasdaq 100 bests EZU hasn’t happened since December 16, 2022. If that holds, it would be only the sixth time this has happened in the past 15 years.

(My kingdom for an MSCI ACWI ex-US ex-Korea ETF... bonus points if you can throw in an ex-Taiwan, too!)

The lesson seems to be: peace is great; the small pieces that help the brains of the AI boom access information are even better.

markets

TeraWulf jumps on 1-gigawatt Kentucky data center site acquisition

TeraWulf shares are rising after the company announced it has acquired a 1-gigawatt hyperscale data center site in eastern Kentucky.

The project, known as the Muskie Data Campus, marks an expansion of the company’s digital infrastructure capabilities and accelerates TeraWulf’s transition from a bitcoin miner into an HPC and AI infrastructure provider. The newly acquired site spans 285 acres and is engineered to support more than 1 gigawatt of data center capacity over time, with the first 500 megawatts scheduled to ramp up in the second half of 2028.

The Muskie Data Campus represents TeraWulf’s second major digital infrastructure campus in Kentucky, alongside the company’s 480-megawatt Justified Data campus in Hancock County.

“This acquisition further reinforces the strategy we discussed on our first quarter earnings call: securing and developing large-scale, power-advantaged sites capable of supporting the next generation of HPC workloads,” Paul Prager, chairman and CEO of TeraWulf, said. “As we said then, the defining constraint in this market is no longer computing hardware — it is power, transmission infrastructure, and execution certainty.”

TeraWulf reported strong Q1 earnings results in early May. While heavy capital expenditure resulted in a GAAP loss, the company generated $34 million in revenue. The stock is up more than 120% year to date.

markets

Wolfspeed and Navitas soar on positive spillovers from Huawei tech breakthrough, guidance boost from peer

Shares of Wolfspeed and Navitas Semiconductor are rising after power chip company Vicor boosted its Q2 guidance and a potential technological breakthrough by China’s Huawei is helping to boost US chip stocks with a big Asia footprint.

Vicor attributed the strong guidance in part to “royalties from an additional licensee to its patented power system technology.” Wolfspeed is a little more upstream from Vicor in the power chip industry as a silicon carbide producer.

Huawei, one of China’s national tech champions, said it’s developed a “LogicFolding” technology that will allow it to start producing 1.4-nanometer chips by 2031.

This announcement helped lift sentiment across Chinese semiconductor names. Semtech, another stock with historically elevated sales exposure to Asia, was up big in early trading but pared most of its gains. ASML is modestly lower, perhaps a nod to the idea that Huawei’s ability to manufacture chips this tiny without its top-notch EUV lithography machines (in light of export restrictions to China) undercuts its critical role in advanced semiconductor manufacturing.

(The irony of any US stocks going up on a Chinese tech self-sufficiency push is not lost on us, especially given competition from Chinese silicon carbide suppliers helped push Wolfspeed into Chapter 11 bankruptcy!)

TSMC, for its part, plans on having chips that small in mass production by 2028.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.